New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Carrington Labs Reports Q3 Revenues Up 16% to $5.1 Million

- Top And Bottom Lines Improve Sequentially For Second Straight Quarter
- Revenues For Consumer Products Subsidiary Caraloe Climb 78%,
Specialized Manufacturing Grows 75%
- Net Loss Of $541,000 Due To Significant Investment In Development Of
Promising GelSite(TM) Drug-Delivery Technology

IRVING, Texas, Nov. 14 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (Nasdaq: CARN), citing substantially increased sales by its Caraloe Inc. subsidiary, today reported third-quarter revenues increased 16 percent to $5.1 million from $4.4 million a year earlier. The net loss for the quarter ended September 30, 2002, was $541,000, or 5 cents per share, compared with net income of $77,000, or 1 cent per share, in 2001. The loss was attributed primarily to research and development expenditures of $586,000 for the DelSite subsidiary that began operations this year.

Excluding the DelSite expenditures, Carrington would have recorded net income of $45,000, or slightly above break-even per share.

For the nine months ended September 30, 2002, total revenues were $13.2 million compared with $13.4 million the prior year. Including expenditures of $1.3 million in DelSite research, the net loss was $2.4 million, or 25 cents per share, compared with net income of $363,000, or 4 cents per share, the first nine months of 2001.

Revenues Increase

"We remain committed to our strategy to increase revenue and reduce losses from quarter to quarter. I am encouraged by the gains in raw material sales and specialized manufacturing revenues by our Caraloe consumer products subsidiary," said Dr. Carlton E. Turner, president and chief executive officer. "Raw material sales and specialized manufacturing are two key areas we targeted for growth during the second half of this year."

Third quarter revenue increased more than 36 percent over revenue recorded in the first quarter of this year and more than 16 percent higher than revenue posted in the second quarter. The loss also narrowed in each of those quarters.

Third quarter revenues for Caraloe increased 78.6 percent to $3.0 million from $1.7 million for the third quarter of 2001. Raw material sales increased by $966,000 to $2.2 million and specialized manufacturing revenue increased $334,000 to $779,000.

Revenue for medical products, consisting primarily of wound-care products, declined about 21.6 percent to $2.1 million from $2.7 million in 2001. The decrease was attributed largely to decreased orders from Carrington's exclusive distributor.

Carrington Increases Investment In GelSite(TM) Development

"Our investment in further development of the GelSite(TM) technology, which we are currently funding entirely through our DelSite subsidiary, was $586,000 during the third quarter, compared with no expenses a year earlier," Turner said. "That also represented a more than 50 percent increase from the second quarter of this year.

"We will continue funding further development of what we view as a highly promising technology to address vital current and anticipated needs in the market," Turner said. "At the same time we are actively seeking partnerships with major pharmaceutical companies that would benefit from utilizing GelSite for controlled delivery of their existing and planned protein- and peptide- based drugs."

DelSite has established relationships with Southern Research Institute and Texas A & M University to facilitate its research and development and partnering efforts. The overall drug delivery market is estimated at $40 billion annually and projected to grow to $70 billion by mid decade. DelSite is targeting a segment of the market estimated at $18 billion annually and projected to grow to $40 billion by 2006.

Solid Balance Sheet

Carrington completed the third quarter with a cash balance of $2.4 million compared with $3.5 million at year-end 2001. The company's current ratio was about 2.8 to 1. The quick ratio was 1.3 to 1. Carrington has no significant long-term debt.

About Carrington

Carrington Laboratories, Inc., is an ISO 9001-certified, research-based biopharmaceutical company currently utilizing naturally occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care; manufacture and market the nutraceutical raw materials Manapol(R) and Hydrapol(TM); and market consumer products under the AloeCeuticals(R) brand. Manapol is the only product available from the Aloe vera L. plant that carries a DSHEA (Dietary Supplement Health and Education Act of 1994) claim that it promotes and enhances immune system activity. Carrington's technology is protected by more than 120 patents in 26 countries. Select products are honored with the internationally coveted CE mark, recognized by more than 20 countries around the world.

Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the company's management; delays or problems in production; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10K filed November 14, 2002.

ZILA Announces Fourth Quarter and Year-end Results; Company Resolves Remaining Accounting Issues

PHOENIX--(BUSINESS WIRE)--November 14, 2002--Zila, Inc. (Nasdaq:ZILA), announced that it has resolved all remaining accounting issues related to its prior financial statements and filed its Form 10-K for fiscal year 2002. Zila said on October 24 that it had agreed to restate certain aspects of its previously issued financial results to reflect generally accepted accounting principles and that certain discussions were ongoing with the Securities and Exchange Commission. These discussions have now been concluded without significant additional adjustments and with no adjustments for the valuation of certain purchased technology rights for Tolonium Chloride, the active ingredient in the Company's OraTest(R) oral cancer detection product. All results discussed in this press release reflect the agreed-upon restatements.
Zila reported revenues for the fourth quarter of fiscal year 2002 (ended July 31, 2002) of $8.8 million, as compared with revenues of $8.9 million; and a net loss from continuing operations of $1.4 million, compared with net income from continuing operations of $623,000 in the year-ago quarter. The Company reported a net loss for the quarter of $1.9 million, or $0.04 per share diluted, compared with net income of $673,000, or $0.02 per share diluted. Cash flow from operating activities for the fourth quarter of fiscal 2002 was positive.

Revenues for fiscal 2002 were $34.9 million, compared with $30.7 million in 2001. Net loss for fiscal 2002 was $12.1 million, or $0.27 per share diluted, compared with a net loss of $6.4 million or $0.15 per share diluted for fiscal 2001. Related to continuing operations, Zila reported a net loss of $11.3 million in fiscal 2002, compared with a loss of $6.3 million in fiscal 2001. Included in fiscal 2002 is approximately $4.0 million of tax expense compared to $379,000 of tax benefit in 2001.

The restatements referenced above also affected Zila's results for fiscal 2000. As restated, Zila reported net income of $3.3 million, or $0.08 per share diluted, on revenues of $36.6 million. Zila's net income from continuing operations for fiscal 2000 was $3.2 million.

Douglas D. Burkett, Ph.D., Chairman, Chief Executive Officer and President, said, "We accomplished a $1.1 million EBITDA turn-around from the third quarter to the fourth, and achieved positive cash flow from operating activities, even as we increased emphasis in our core competency areas. We began fiscal year 2003 with a new management team, an untapped line of credit, profitable pharmaceutical and nutraceutical product lines, and promising research in our biotechnology unit."

Dr. Burkett continued, "We have now completed the restatement process. With considerable progress already made in streamlining the Company and refocusing on our core strengths, we are aggressively pursuing our goal of producing break-even-to-positive EBITDA and revenue growth in fiscal 2003, with maximum transparency and credibility."

Fourth Quarter Fiscal 2002 Highlights:

Dr. Burkett, who was elected president and chief executive officer in June 2002 and chairman in September 2002, has implemented a new strategy for the Company, focusing on its core competency in pharmaceuticals, nutraceuticals and biotechnology.

Fourth quarter accomplishments included:


-- Cost reductions throughout the Company and elimination of
unprofitable products and endeavors;

-- Generating growth through allocation of greater resources to
core competency areas, including increased marketing for
Zilactin(R) oral care and Ester-C(R) vitamin products, and

-- An investment of over $700,000 in the OraTest Phase III
clinical trial -- an increase of approximately $400,000 over
the same quarter a year ago;

-- Innovative Swab Technologies' receipt of a large contract that
is expected to double that business unit's sales in fiscal
2003; and

-- Hiring of new operating management for Zila's nutraceutical
and pharmaceutical businesses and substantial organizational
restructuring throughout the Company.
During the third quarter of fiscal 2002, management determined that completion of the OraTest Phase III clinical trial will require a substantial number of additional patients. The requirement for the larger number of patients is related to the tumor formation rate within the study population and not to the efficacy of the OraTest product. In order to support the larger number of patients needed to complete the trial, management intends to increase the rate of funding for the trial and the number of clinical sites.

In recent months, management began efforts to transition the clinical trial from ILEX(TM) Oncology Services, Inc., to a new, larger, more experienced global contract research organization (CRO). Zila requested proposals from several of the largest, highest quality and most prominent CRO's with worldwide capabilities, and received fee quotations from each. Management is in the process of finalizing the selection of a new global CRO with access to clinical sites in high-density oral cancer regions around the world. Each CRO agreed that the trial could be transitioned successfully without compromising any of our current research data. After its selection and retention, the new CRO will work to optimize the study protocol and provide estimates for total patients, costs and milestone dates for the trial.

Zila believes that it will have sufficient funds for the clinical trial for the next fiscal year. The Company will, however, require additional financing to support the OraTest clinical trial, regulatory, manufacturing and marketing costs extending beyond fiscal 2003. Management is currently considering possible financing sources such as strategic partners and is pursuing funding strategies that, if completed, would provide significant funding for the clinical trial. Management is also considering the possible liquidation of certain Zila assets outside the Company's areas of core competency as part of Zila's new focus on core strengths and objectives. These assets could also provide significant funding for the clinical trial. There is no assurance that such funds will be available on terms acceptable to the Company.

Fourth Quarter Fiscal 2002 vs. Fourth Quarter Fiscal 2001

The Company had a negative EBITDA from continuing operations of $86,000 in the fourth quarter of fiscal 2002, compared to a positive $1,580,000 in the year-ago quarter. Cash flow from operating activities for the fourth quarter of fiscal 2002 was positive.

The principal reasons for the fourth quarter loss compared with the year-ago quarter were:


-- An approximate $400,000 increase in OraTest clinical trial
spending;

-- Increased expenses of approximately $400,000 related to the
launch of the new ViziLite(TM) product;

-- An approximate $300,000 decrease in the value of Zila
Nutraceuticals' saw palmetto inventory after discovery of some
spoilage following the close of the quarter; and

-- A decrease in net income at Zila Nutraceuticals of $800,000,
due primarily to proceeds received from a litigation
settlement in the fourth quarter of last year.

Fiscal 2002 vs. Fiscal 2001
Net loss from continuing operations for fiscal year 2002 was a negative $11.3 million compared with a negative $6.3 million for fiscal year 2001. The reduction in profitability is due primarily to tax expenses (discussed below), product launch expense in fiscal 2002 for the ViziLite(TM) product, saw palmetto inventory spoilage and reduced profitability in the Zilactin product line, partially offset by improved profitability for Ester-C products and reduced expenses at Zila Europe.

As a result of its net losses for fiscal 2002 and 2001, the Company determined that it is more likely than not that certain future tax benefits will not be realized. As a result, the Company reported income tax expense of $4.0 million due to the increase in its tax valuation allowance.

Conference call

The Company will hold a conference call on Monday, November 18, 2002 at 11:00 a.m. Eastern time (9:00 a.m. Phoenix time), to discuss its fourth quarter and year end financial results for fiscal 2002. For access to the conference call, please dial 1-800-289-0528 (code 527111). A replay of the conference call will be available from 2:00 p.m. (ET) on November 18, 2002, through November 20, 2002, at 1-888-203-1112 (code 527111). In addition, the call will be broadcast over the Internet and can be accessed by entering ZILA at http://www.opencompany.info. Investors should go to the website prior to the call to download any necessary audio software.

The Company has also set November 22, 2002, as its record date for the Annual Shareholders Meeting, which will be held on Tuesday, January 14, 2003, at 9:00 am local time at the Marriott Camelback Inn, 5402 East Lincoln Drive, Scottsdale, Arizona.

As part of management's program to raise its profile with the investment community, Dr. Burkett will make a presentation at the November 23 Red Chip Partners(TM) Phoenix Investors Conference.

About Zila

Zila, Inc., headquartered in Phoenix, is an international provider of healthcare and biotechnology products for dental/medical professionals and consumers. Zila has three business units: Zila Pharmaceuticals, marketer of Zilactin(R) oral healthcare products, Peridex(R) prescription mouth rinse and ViziLite(TM) oral examination kits, and manufacturer of patented swabs at Innovative Swab Technologies; Zila Nutraceuticals (Inter-Cal Nutraceuticals), manufacturer of patented Ester-C(R) branded products and Palmettx(R) Saw Palmetto; and Zila BioTechnology, developer of OraTest(R) oral cancer detection products and Zila(R) Tolonium Chloride technologies for cancer and pre-cancer detection and treatment. For more information, visit www.zila.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2002, filed with the Securities and Exchange Commission.

Studies Show Pycnogenol® Useful in Treating Diabetes

CHICAGO - November 14, 2002- In a recent clinical study, the powerful natural antioxidant, Pycnogenol helped 30 diabetics ward off one of the most debilitating affects of the disease, diabetic retinopathy involving bleedings in the eye, which can lead to blindness. The study, which was published in Phytotherapy Research, concluded that Pycnogenol helped slow progression of diabetic retinopathy (blindness) by sealing the leaky capillaries that cause the condition.

During the two-month a clinical study, participants showed no deterioration of retinal function and some showed a significant recovery of visual acuity in comparison to the progressively worsened condition of the ten patient placebo-treated group.

Diabetic retinopathy is the leading form of blindness in people under the age of 60 in the US and affects more than 5.3 million Americans. Some diabetics are looking to natural sources to keep their eyes healthy. Pycnogenol has shown a positive affect in five clinical studies, including more than 1,000 diabetics, in strengthening the tiny capillaries in the eye. Researchers conducted the studies because Pycnogenol has been shown to strengthen the circulatory system in dozens of studies over the last two decades.

According to Jesse Lopez, Executive Vice President of Natural Health Science, "Based on this scientific evidence and the results from four additional clinical studies, a new Pycnogenol product, Picno 30(TM), was developed by Novartis specifically for the treatment and prevention of diabetic retinopathy and is available in Europe."

In addition to the extensive research in diabetic retinopathy, Pycnogenol has been studied in connection with other complications associated with diabetes. Diabetes increases the production of free radicals, which damage the body by increasing the risk of heart attack, nerve damage, cataracts, blindness and stroke. Antioxidants are known for their combative properties against free radicals and according to the recent book PycnogenolÒ For Superior Health by Richard A. Passwater, PhD., "Diabetics need more antioxidant protection than healthy persons. Pycnogenol is the most powerful antioxidant nutrient known at this time."

While Pycnogenol helps guard against health risks linked to diabetes, the super antioxidant also increases the body's defenses, like Vitamin C and E, to maintain general health. Most importantly, Pycnogenol has been extensively researched for its safety and can be taken continuously without side effects.

###

Natural Health Science, LLC, (NHS) based in Hillside, New Jersey, is the North American distributor for Pycnogenol® brand French Maritime Pine Bark Extract on behalf of Horphag Research. Pycnogenol is a registered trademark of Horphag Research Ltd., Guernsey, and its applications are protected by U.S. patents #4,698,360 / #5,720,956 / # 6,372.266 and other international patents. NHS has the exclusive rights to market and sell Pycnogenol®
(pic-noj-en-all) and benefits from over thirty years of scientific research assuring the safety and efficacy of Pycnogenol® as a dietary supplement. For more information about Pycnogenol® visit our web site at www.pycnogenol.com.

Forbes Medi-Tech's Cholesterol-Lowering Oil Featured in Presentation at American Heart Association Conference

Vancouver, British Columbia - November 14, 2002 Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced that the results of its latest designer cooking oil clinical trial will be presented at the American Heart Association's (AHA) Scientific Sessions 2002 conference in Chicago, IL on November 18, 2002. The clinical trial completed earlier this year at McGill University was shown to help participants lose weight and lower their cholesterol levels.

"This conference is a good opportunity to demonstrate the significance of Forbes' designer cooking oil," said Jerzy Zawistowski, Vice President, Functional Foods & Nutraceuticals, Forbes Medi-Tech Inc. "Having the AHA accept the study abstract for presentation at this conference is a boost to
the credibility of the designer oil study and its results", said
Zawistowski.

In a clinical study announced in May 2002, 24 healthy men on a controlled
diet incorporating Forbes' "designer oil" showed a statistically
significant decrease in total body weight tissue in 28 days. Study
participants who received olive oil in their diet (control group) did not
demonstrate any changes in body compartment volumes. In addition,
participants who consumed designer oil showed a decrease of Low Density Lipoprotein (LDL) cholesterol concentrations. The Statistical results will be presented at the conference in Chicago.

About the American Heart Association
The American Heart Association is a national voluntary health agency whose mission is to reduce disability and death from cardiovascular diseases and stroke. The American Heart Association and its affiliates support research activities broadly related to cardiovascular function and diseases, stroke, basic science, clinical, bioengineering/biotechnology and public health problems. The American Heart Association's Scientific Sessions is the world's largest convention for scientists and healthcare professionals devoted to the science of cardiovascular disease and stroke. Over 25,000 people attended the 2001 conference.

About Forbes Medi-Tech Inc.
Forbes Medi-Tech Inc. is a biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceuticals
and nutraceutical products for the prevention and treatment of
cardiovascular and related diseases. By extracting plant sterols from wood pulping by-products, Forbes has developed cholesterol-lowering agents to be used as pharmaceutical therapeutics, dietary supplements and functional food ingredients.

NASDAQ and the Toronto Stock Exchange have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This press release contains certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act and Section 21E of the U.S. Securities Exchange Act of 1934, which statements can be identified by the use of forward-looking terminology, such as, "will", "to", "can" or comparable terminology referring to future events or results. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, research and development risks, including the fact that further research and clinical trials are needed for designer oil which may not proceed or if they do, may not duplicate results of previous trials or otherwise demonstrate anticipated results; the fact that presentations and conferences may not proceed as currently scheduled;
and intellectual property risks. See the Company's reports filed with the
Toronto Stock Exchange, the B.C. and Ontario Securities Commissions, and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying other important factors with respect to such forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward-looking statements. The Company assumes no obligation to update the information contained in this press release.

New Discovery to Extract Hydroxytyrosol From the Pulp of Organic Olives Leads to Development of Olivenol™

Hayward, CA—Forget olive stems and pits. Leave the olive leaf behind. A new technological breakthrough from CreAgri now shows that the olive’s greatest health benefits come from its water. And that new Olivenol™, a dietary supplement produced from the water of organic olives, provides the highest concentration of HYDROXYTYROSOL, one of the most potent natural antioxidants.

Olivenol™ is the first and only dietary supplement in the world to contain hydroxytyrosol, the primary polyphenol antioxidant found in the pulp of olives. The new supplement is available in tablets, vegetarian capsules or liquid form.

Worldwide research indicates that hydroxytyrosol, typically found in extra virgin olive oil, is among the most potent antioxidant found in nature and provides most of the health benefits associated with the Mediterranean diet. CreAgri has developed a new proprietary process to isolate this important compound from the water contained in the pulp of olives.

In its efforts to redefine practices in the olive industry, CreAgri uncovered surprising beneficial properties in olive water, the otherwise wasted by-product of extra virgin olive oil extraction. A closer examination of olive water by CreAgri founder and biotech pioneer, Dr. Roberto Crea, revealed it to be an antioxidant powerhouse.

“While polyphenol antioxidants are present in olive oil, the water extracted from the pulp contains even greater concentrations—300 to 500 times greater,” said Dr. Crea. “These polyphenols include hydroxytyrosol, the polyphenol identified as having the highest free-radical protection ever reported for an antioxidant compound.”

In fact, the Oxygen Radical Absorbance Capacity (ORAC), or industry measurement of antioxidant activity, demonstrates that pure hydroxytyrosol has an ORAC value of approximately 27,000 compared to other antioxidants like oleuropein (olive leaf) which measures at 12,000, epicatechin (green tea) at 8,100, proanthocyanidins (grape seed) at 6,200.

Olivenol™ is the first antioxidant made from the olive fruit, or pulp, and contains HIDROX™, CreAgri’s patented form of hydroxytyrosol.

New Technology from CreAgri Delivers Both and Industry Solution and Widespread Consumer Health Benefits.

CreAgri is the first company to use proprietary technology to redefine practices in the olive oil industry by extracting wastewater generated from the production of extra virgin olive oil and turning it into a valuable source of antioxidant compounds. The company has two U.S. patents on its processes for recovering hydroxytyrosol from olive water and a third patent on composition of matter. CreAgri’s patented technological breakthrough is called Integrale™, and it produces olive water that is free from pit impurities and high in active antioxidants.

CreAgri has developed the proprietary, two-step method, which first removes the pits before olives are pressed to extract oil, a crucial step to ensuring high-yield antioxidant recovery. In traditional oil extraction methods, pits are not removed prior to milling, which results in impure olive water that the industry typically disposes of as waste.

In its second patented step, CreAgri processes the polyphenolic-rich olive water to avoid air and bacterial oxidation and to further release the highest quantities of hydroxytyrosol.

The Integrale™ process provides an economical solution to the most troublesome problem in the olive oil industry—it eliminates the production of an otherwise waste product. Most importantly, however, the Integrale process allows CreAgri to produce Olivenol™, an unprecedented good health discovery for consumers.

Olivenol™: Nature’s New Gift for Preserving Good Health

The natural antioxidant benefits of the olive are well documented and continue to capture the interest of medical science and the media. Polyphenols from extra virgin olive oil have been linked to healthier breast tissue, improved colon function, lowered cholesterol, and better cardiovascular health, as well as the reduction of stress from secondary smoke and the prevention of skin damage. Polyphenols also have anti-bacterial and anti-viral properties. Additional benefits include better hair, skin and nails.

Olivenol™ offers the polyphenol antioxidant benefits of the Mediterranean diet without the fat and calories. One dose provides the same antioxidant effect as four to six ounces of extra virgin olive oil.

CreAgri is committed to promoting human health and well being through the creation of superior, natural products. The company focuses on the development of science-based processes that are environmentally friendly and compatible with sustainable agricultural methods. CreAgri’s headquarters are in Hayward, California. The olives grown on the company’s own organic olive ranch are carefully processed within 48 hours of harvesting.

# # #

Anti-Aging Pioneers Join Market America to Prove Age is Just a Number

Drs. Ronald Klatz and Robert Goldman Partner with Market America to Develop Cutting-Edge Anti-Aging Products

GREENSBORO, NC - Market America, a leading product brokerage and one-to-one marketing company, today announced a strategic partnership with renowned anti-aging research pioneers, Drs. Ronald Klatz and Robert Goldman. The combination of Market America's mass customization capabilities and the cutting-edge technologies developed by Klatz and Goldman will provide advanced products designed specifically to address the health issues of an aging population.

"Market America is very pleased to enter into this partnership," said Dennis Franks, executive vice president, Market America. "Klatz and Goldman are leading the charge into the future of health. Growing old used to be thought of as unavoidable. They have virtually created the anti-aging industry and are proving that growing old does not mean living a less productive life."

Through a joint research and development pact, the recently unveiled partnership will promote and market new products and concepts designed to prevent health risks associated with aged metabolism.

"Market America offers not only an impressive line of products but also the unique capability to produce and mass customize products," said Dr. Ronald Klatz, founder and president, American Academy of Anti-Aging Medicine, and co-founder, National Academy of Sports Medicine. "They are leading their industry with customized products designed for a demanding market. We are eager for the opportunity to explore the possibilities this partnership offers."

The partnership will focus its resources on developing innovative products designed for an aging baby-boomer population. With the median age moving upwards as the baby-boomers draw closer to retirement, the treatment of age-related disorders, currently a $30-billion industry, is expected to top the trillion-dollar mark worldwide.

"Anti-aging is the future of healthcare. We are only beginning to discover the potential of proactive intervention to help keep people young," said Dr. Robert Goldman, president, National Academy of Sports Medicine, and co-founder and chairman, American Academy of Anti-Aging Medicine. "Our partnership with Market America allows us to leverage an established line of production to further promote and advance the anti-aging field."

ABOUT MARKET AMERICA

Headquartered in Greensboro, N.C., Market America provides a method of achieving financial independence with its proven UnFranchiseR Business Development System and market-driven products. Founded in 1992, Market America has experienced explosive growth and achieved more than $1 billion in suggested retail sales. The Company has more than 85,000 distributors worldwide and has recently expanded its operations into Australia. Market America is leading its industry with bold Internet technology, One-to-One Marketing and Mass Customization. The cutting-edge marketplace Mall Without Walls(tm) can be found at www.marketamerica.com. Market America is changing the face of business, one customer at a time.

ABOUT DR. RONALD KLATZ

Dr. Ronald Klatz is recognized as a leading authority in the field of anti-aging medicine, the inventor, developer or administrator of over 100 scientific patents and has authored over 36 books. As the founder and president of the American Academy of Anti-Aging Medicine, he has pioneered the exploration of new therapies for the treatment and prevention of age-related degenerative diseases. As President of the Academy, Dr. Klatz oversees educational programs for more than 10,000 physicians and scientists from 65 countries.

ABOUT DR. ROBERT GOLDMAN

Dr. Robert Goldman as devoted his multi-faceted career to the advancement of human health and performance. He is the chairman of the International Medical Commission overseeing the sports medicine committees in over 176 nations. He is also founder and international president of the National Academy of Sport Medicine and co-founder and chairman of the American Academy of Anti-Aging Medicine.


###

Cold Snap™ Owner Semi-Finalist in Microsoft Ms. M.o.X.i.e National Contest

Hannah Hayes Only Colorado Businesswomen Selected

Evergreen, CO —Oriental Herb Company (OHCO), maker of best-selling Cold Snap™, announces that the company’s owner, Hannah Hayes is a top-ten semi-finalist in Microsoft’s nationwide Ms. M.O.X.I.E. contest. The contest was held to find savvy, entrepreneurial businesswomen who use Microsoft office for Mac to stay ahead of the pack in business. Ms. Hayes is the only Colorado businesswoman selected.

From November 12 through November 29, the semi-finalists will be posted on www.mactopia.com. The public is invited to vote for their favorite candidate via an online polling page. At the end of the voting period, three finalists will be determined, based on the highest number of votes received. Judges from Microsoft will select the winner on/about December 4, 2002.

The essay on Ms. Hayes outlines her determination and moxie in starting and succeeding at developing OHCO and its line of Chinese herbal formulas. With just the products, her spirit, and courage, Hannah has grown sales solely by word-of-mouth. Her grass roots philosophy of marketing has developed Cold Snap™ into Colorado’s leading herbal formula, with tens of thousands of loyal users.

Hannah and her husband, Donn, a longtime practicing acupuncturist and staff herbalist, founded OHCO in 1994. With products currently distributed in over 500 health food stores nationwide, OHCO prides itself on personalized customer service and a money-back guarantee. For more information on OHCO, its formulas, or its founders, please contact OHCO at 800.344.2466 or via the web at www.ohco.com.

###

Merical Vita-Pak Appoints Kitty Murphy Account Manager

Anaheim, CA – Merical Vita-Pak Inc., a closely held custom contract packaging company specializing in the nutrition industry, today announced that Kitty Murphy has been named Account Manager.

Ms. Murphy most recently served as Purchasing Manager for the Nutrilite Division of Access Business Group (formerly Amway). At Nutrilite, she was instrumental in transitioning the company’s purchasing department from a traditional structure into Strategic Procurement, with an emphasis on driving down the total cost of inventory ownership. She brings to MVP nearly twenty years of experience in the nutrition industry and is a former president and active member of the Pacific Technology Exchange, past General Chair of the Drug, Chemical, and Allied Trade’s DCAT West program, and participating member of the Institute of Supply Management (formerly NAPM).

In making the announcement, D. Dean Baltzell, Chairman and CEO of Merical Vita-Pak Inc. said, “Kitty’s experience in the vitamin industry and in project management will greatly enhance our ability to service our strategic accounts and grow our business. She is a tremendous addition to the experienced and successful customer service oriented organization we’ve created.”

About Merical Vita-Pak Inc.

MVP provides custom primary packaging for the vitamin, herbal, nutritional, and pharmaceutical markets, and also secondary packaging services to a variety of other industries. Since beginning operation more than thirty years ago, MVP has grown into one of the largest custom contract packagers in the western United States. The company’s success is based on exceptional service and quality. MVP maintains licenses with the state and federal FDA, California Board of Pharmacy, and NNFA.

# # #

Bravo! Foods Reports Third Quarter Results

NORTH PALM BEACH, Fla., Nov. 12 /PRNewswire-FirstCall/ -- Bravo! Foods International Corp. (BULLETIN BOARD: BRVO) , a brand development and marketing company that holds the Looney Tunes(TM) license to manufacture, promote and distribute flavored milks, today announced its financial results for its third quarter ended September 30, 2002. The company reported revenue of $308,729 as compared to the previous year level of $256,971 and the prior quarter of $496,179. The reduction in revenue in the current quarter was the result of retailers deferring orders pending the availability of Bravo! Foods' new vitamin and mineral fortified Slammers line of single serve flavored milk.

The Company reported a quarterly cash loss (defined as a loss before depreciation, amortization, non-cash stock compensation charges and deemed dividends accruals) of $519,912 or $0.02 per share for the third quarter of 2002, compared to a cash loss of $441,000 or $0.03 per share for the second quarter of 2002 and a cash loss of $392,426 or $0.03 per share for the third quarter of 2001. General and administrative costs in the quarter totaled $882,555. The Company reported a net loss applicable to common stockholders of $1.0 million or $0.05 per share for the quarter, which compares to a net loss of $1.4 million or $0.08 per share in the second quarter of 2002 and $497,324 or $0.04 per share in the third quarter of 2001.


Roy Warren, Bravo! International's chief executive officer: "This quarter marks the completion of a transitional period for the company. Our revenues this quarter fail to reflect the progress we have made over the past three months. The long awaited launch of our vitamin and mineral fortified Slammers line, necessitated the simultaneous conversion of our entire product line to the new formulation and packaging. Many food retailers and food service establishments, anticipating our new product line, held off introducing the existing Bravo! Product offering until the new fortified Slammers were ready to ship. This delay had a marked impact on our revenues for the quarter."


Mr. Warren continued, "During the quarter, we introduced Slammers and dramatically expanded our distribution to include all 50 states and Canada in both the dairy and juice aisles of supermarkets. In addition, we launched our Slammers product in 5300 7-Eleven convenience stores nationwide and the U.S. Public School System in four states. Of significant importance, we have made meaningful strides in improving our balance sheet and anticipate stronger fourth quarter revenues with the shipment of our new Slammers line."


QUARTER HIGHLIGHTS AND RECENT EVENTS
* Bravo! Foods' Looney Tunes(TM) Brand Flavored Milk Introduced Vitamin
Enriched 'SLAMMERS' Line and Received Industry Distinction
Company fortifies its premium milk line with 11 essential vitamins and
minerals. Dairy Food Magazine hails Slammers as one the top new dairy
foods of 2002 in its annual "Best New Products of 2002" issue.
* Bravo! Foods Added Twelve Supermarket Chains and Five Food Distributors
to its Customer List During the Quarter
Approximately 1,225 East and Southeast supermarket stores, from
Massachusetts to Alabama, will now be offering Bravo! Foods healthy
milk line. Royal Ahold's Bi-Lo and Bruno's, together with Great
Atlantic & Pacific Tea Company, Gristedes, Krasdale, Met Foods and
Pioneer are among the large chains that have added the milk line over
the last three months. CNS Metro, White Rose, U.S. Food Service, A.E.
Wease Distributing and Cash-Wa are new distributors of the premium milk
line.
* Bravo! Foods' Looney Tunes(TM) Brand Flavored Milk Entered Canada
During the quarter, the Bravo! Foods contracted with Farmers
Cooperative Dairy Limited of Canada to manufacture and distribute its
premium flavored fluid milk throughout Canada. Bravo! Looney Tunes(TM)
brand flavored milk is available in grocery and convenience stores
within Atlantic Canada region. A national Canadian roll out is
expected early 2003.
* Farmland Dairies LLC, a Division of Parmalat USA Corp. Began Shipment
of Slammers in Eight-Ounce Aseptic Tetra-Brik
Aseptic Slammers Fortified Reduced Fat Milk(TM) is available in five
flavors in multi and variety packs in the juice aisle. Currently,
aseptic Slammers is available in all Pathmark stores and is scheduled
to be available in an additional 1500 northeast supermarket stores by
the end of the year. Parmalat expects distribution to exceed 3400
stores by first quarter 2003.
* Bravo! Foods Launched Its Premium Flavored Milk Line into Convenience
Store Industry
Up to 5,300 participating 7-Eleven stores are the first convenience
stores to offer Bravo! Foods Looney Tunes(TM) Brand Slammers. This
event jettisons Slammers into becoming a nationally distributed milk
line.
* Slammers Fortified Reduced Fat Milk(TM) Enters U.S. Public School
System
32,500 children in 55 schools in Missouri, Nebraska, Pennsylvania and
Tennessee are the first to enjoy Bravo! Foods' healthy premium flavored
milk line.
* Bravo! Foods Introduced Beng Beng Le Flavored Milks and Yogurt in China
Through a cooperative effort between its wholly owned subsidiary China
Premium Food and Wonder Sun Dairy, Bravo! Foods branded a new line of
ultra-high temperature (UHT) bottled Looney Tunes(TM) branded flavored
milk and drinkable yogurts.
* Bravo! Foods International Corporation Announced Institutional Investor
Participation
Mid Am Capital, L.L.C., a finance affiliate of Dairy Farmers of
America, made a $1 million investment in Bravo! Foods. The proceeds
are being used to promote marketing initiatives for the Company's new
Slammers products, for general working capital and to improve the
Company's balance sheet.

About Bravo! Foods

Bravo! Foods holds a license from Warner Bros. Consumer Products to utilize the Looney Tunes(TM) characters and names on milk products throughout the fifty U.S. States, Puerto Rico, the U.S. Virgin Islands, Canada, China and Mexico. The milk is available in the U.S. through production agreements with milk processors. It is currently available in five flavors under the brand name Slammer Fortified Reduced Fat Milk(TM) and can be purchased in retail outlets in all fifty U.S. states and is also internationally available in Canada, China and Mexico.

LOONEY TUNES, characters, names and all related indicia are trademarks of and (c) WarnerBros. (02)

Safe Harbor under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, regulatory approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties as may be detailed in the Company's filings with the Securities and Exchange Commission.

CRN Issue Guidelines for Young Athletes on Responsible Use of Sports Nutrition Supplements

-Urges Gatekeepers to Assist in Effort-

WASHINGTON, D.C., November 13, 2002-The Council for Responsible Nutrition (CRN), one of the dietary supplement industry's leading trade associations, has released "Guidelines for Young Athletes: Responsible Use of Sports Nutrition Supplements" to provide educational assistance to young athletes, their gatekeepers, health care professionals, and industry.

According to John Cordaro, president and chief executive officer, CRN, "Our member companies manufacture a range of sports nutrition products, from basic vitamins and minerals to energy bars to muscle recovery agents. Our members recognize that not all sports supplements are appropriate for all people and must be used in accordance with label directions. CRN intends these guidelines to encourage parents, coaches and trainers to provide oversight for appropriate use, or in some cases non-use by young athletes, of these products. The dietary supplement industry is stepping up to the plate by providing this useful information to those who can influence young athletes. Sports authorities and health professionals are urged to support and distribute these guidelines. Together, we can help ensure that our young athletes balance the desire to win with the need for proper use of sports nutrition products."

Mr. Cordaro continues, "Sports nutrition supplements can play an important and positive role for athletes. But they must be used as supplements, not substitutes, to an overall healthy regime that includes a well-balanced diet, proper exercise and conditioning, dedication, and hard work."

The guidelines urge all athletes to engage in the proper use of sports nutrition supplements, including following label directions such as dosage information and cautions. In addition, the guidelines suggest that parents, guardians, coaches and health care professionals play a role in providing oversight and that young athletes follow the advice from those gatekeepers. The guidelines also point out that governing bodies for various sports may have different and more specific guidelines for many products, including sports nutrition supplements, and that athletes should familiarize themselves with those rules.

The guidelines classify sports nutrition supplements into three categories for young athletes-green, yellow and red.

John Cardellina, vice president, botanical science and regulatory affairs, CRN, explains the "traffic light" format of the guidelines, "In the green light category, CRN has placed products, like fluid or electrolyte-replacing beverages, protein powders and energy bars, that are used as part of a normal diet as an additional source of protein and calories. The green light category also includes basic nutritional vitamins and minerals, since athletes may deplete stores of these vital nutrients during exercise and exertion. It was important to include a yellow light category for products that contain ingredients that affect muscle function or recovery, like creatine. There is no substantiated safety concern for creatine, but its use should be monitored and directions for use carefully followed, as the long-term effects have not been sufficiently studied in younger athletes. CRN has placed products containing ephedrine alkaloids and steroid hormone precursors in the red light category because they clearly should not be used by individuals under the age of 18."

The guidelines were first presented in a preliminary draft to participants at a January 2002 conference on performance-enhancing products co-sponsored by the Office of Dietary Supplements at the National Institutes of Health and CRN. With the official release of the guidelines, CRN is urging athletic organizations and associations, sports authorities, health care professionals, and government agencies to aid in dissemination of the information.

Download Brochure (PDF)
http://www.crnusa.org/pdfs/CRNSNSGuidelines1102.pdf
May be reprinted with permission

--------------------------------------------------------------------------------

The Council for Responsible Nutrition (CRN), founded in 1973, is a Washington, D.C.-based trade association representing ingredient suppliers and manufacturers in the dietary supplement industry. CRN members adhere to a strong code of ethics, comply with dosage limits and manufacture dietary supplements to high quality standards under good manufacturing practices. The dietary supplement industry is regulated by the Food and Drug Administration and the Federal Trade Commission as well as by government agencies in each of the 50 states.